Sales Nexus CRM

Helus Pharma Posts $103.1 Million Q2 Loss as Phase 3 Depression Trial Completes Enrollment

By Advos•
Helus Pharma reported a widening fiscal Q2 2027 net loss of $103.1 million but completed enrollment in its pivotal Phase 3 APPROACH study of HLP003 for major depressive disorder, a key milestone for the clinical-stage company.
Helus Pharma Posts $103.1 Million Q2 Loss as Phase 3 Depression Trial Completes Enrollment

Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) on Monday reported financial results for its fiscal second quarter ended Sept. 30, 2026, disclosing a net loss of $103.1 million, compared with $33.7 million in the prior-year period, while highlighting progress across its pipeline of novel serotonergic agonists. The company, the commercial operating name of Cybin Inc., ended the quarter with $171.1 million in cash and cash equivalents, according to the earnings announcement, which was disseminated on behalf of Helus Pharma.

The widened loss matters to investors because it reflects the mounting cost of late-stage drug development. Operating expenses excluding share-based compensation rose to $39.6 million from $28.5 million a year earlier, primarily reflecting continued advancement of the company's Phase 3 clinical program. Cash used in operating activities totaled $35.3 million, compared with $34.5 million a year earlier, a modest increase that suggests the company's cash burn has remained relatively stable even as its trial activity expanded.

For patients and the mental health sector, the most consequential development may be the completion of enrollment in APPROACH, Helus Pharma's pivotal Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status designed to expedite the development and review of drugs that may offer substantial improvement over existing therapies. Enrollment continued during the quarter in the EMBRACE and EXTEND studies, and the company said it plans to initiate a Phase 2 monotherapy study of HLP004 for generalized anxiety disorder in the first quarter of 2027. It also expects to select a development candidate for its HLP005 program in the second half of 2027.

Helus Pharma is developing synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity, aiming to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions. The company operates in Canada, the United States, the United Kingdom and Ireland. Readers seeking the full financial statement can view the complete announcement at https://ibn.fm/yu74F.

The quarterly update was carried by BioMedWire, a communications platform focused on biotechnology, biomedical sciences and life sciences that is part of the Dynamic Brand Portfolio at IBN. The platform distributes company news through InvestorWire and offers editorial syndication to 5,000+ outlets. For Helus Pharma, the coming quarters will test whether its clinical momentum can translate into regulatory progress before its cash position becomes a constraint.

Advos

Advos

@advos